AUG Therapeutics
AVTX-803
Leukocyte Adhesion Deficiency
Countdown
177days
Phase 3 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 3 trial results for AVTX-803 in Leukocyte Adhesion Deficiency are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05754450: Phase 3 trial, sponsor AUG Therapeutics, drug AVTX-803. Primary completion date 2026-12-31 (estimated).”